Phase Genomics Welcomes David Shoultz as Chief Business Officer
SEATTLE--Phase Genomics, Inc., a leading innovator at the forefront of genomics technology development, has recently announced a significant addition to their executive team. David Shoultz, PhD, MBA, has been appointed as the company’s first Chief Business Officer. His appointment aims to drive growth, enhance market awareness, and amplify the impact of technological advancements in the realm of human health.
Strategic Importance of New Leadership
“David’s experience in leading diverse organizations across various therapeutic areas and global public health is crucial for our growth strategy,” stated Ivan Liachko, PhD, founder and CEO of Phase Genomics. His extensive background in the industry brings the needed expertise at a pivotal time when the company is focusing on accelerating the adoption of its technologies, poised to unlock and integrate new layers of scientific discovery. We are thrilled to welcome David to our team as we reinforce our mission to improve health outcomes worldwide.
David Shoultz's Background
David Shoultz has enjoyed a noteworthy career, including aiding in the launch of Monod Bio, an Institute for Protein Design (IPD) spin-out where he served as co-founder and COO. His previous roles include being a vital member of the global health product development team at the Bill & Melinda Gates Foundation, directing the global drug development program at PATH, and holding scientific leadership positions in various companies such as Neoleukin Therapeutics and PPD. Throughout his career, Shoultz has successfully raised over $150 million in venture capital and non-dilutive funding to support pioneering innovations in health and medicine.
Excitement for the Future
“Phase Genomics has been built on a dedicated and contagious scientific curiosity, which is one of the primary reasons I am proud to join this team on the cutting edge of discovery,” remarked David Shoultz. He acknowledged the company's impressive track record of technological breakthroughs over nearly a decade, signaling that even more advancements are on the horizon. Shoultz emphasized the commitment of Phase Genomics to not only advance leading-edge genomic tools for research but to demonstrate their real-world impact. Together, the team is set to seize significant opportunities that extend beyond laboratory settings, particularly in pressing therapeutic areas like oncology and infectious diseases.
Current Academic Roles
Besides his responsibilities at Phase Genomics, Shoultz holds an affiliate professorship in the Department of Epidemiology at the University of Washington. He serves as a translational advisor within the University’s IPD, showcasing his broader commitment to education and innovation in the field of genomics.
Anticipation of Upcoming Engagements
Shoultz is scheduled to attend the BIO Investor Forum in mid-October, where he will represent Phase Genomics in San Francisco. This engagement illustrates the company’s commitment to fostering connections that will lead to the further development of its groundbreaking technologies.
About Phase Genomics
Phase Genomics utilizes proprietary ultra-long-range genome sequencing technology to facilitate genome assembly and microbiome discovery, in addition to analyzing genomic integrity and chromosomal abnormalities. Their extensive portfolio includes laboratory and computational services, reagent kits, and genomic services, featuring top-tier genome and metagenome assembly software.
Founded in 2015 in Seattle by a dedicated group of genome scientists and software engineers, the company is on a mission to equip researchers with genomic tools that drive transformative discoveries.
Frequently Asked Questions
1. Who is David Shoultz?
David Shoultz is the newly appointed Chief Business Officer of Phase Genomics, bringing extensive experience in global public health and biotechnology.
2. What does Phase Genomics do?
Phase Genomics specializes in genome sequencing technology, enabling significant advancements in genomic research and healthcare.
3. Why is Shoultz’s appointment significant?
Shoultz’s diverse experience is expected to accelerate Phase Genomics’ growth and enhance its technological adoption in healthcare.
4. What type of technologies does Phase Genomics focus on?
Phase Genomics focuses on ultra-long-range genome sequencing as well as tools for microbiome discovery and genomic integrity analysis.
5. What is the vision of Phase Genomics?
The company aims to empower scientists with advanced genomic tools that lead to groundbreaking discoveries, improving health globally.
